The Global Epinephrine Autoinjector Market is used to treat severe allergic reactions like anaphylaxis and food allergy attacks through an automatic injection of epinephrine. Epinephrine Autoinjectors are easy-to-use medical devices pre-filled with epinephrine that are designed for self-administration or administration by others during a severe allergic reaction. The surging cases of food allergies, insect stings, latex allergies and medication allergies have increased the risk of anaphylaxis globally. As per reports, anaphylaxis occurs in approximately 1-5% of the general population, affecting both children and adults. The growing anaphylaxis cases worldwide have driven the demand for epinephrine auto-injectors.
The Global Epinephrine Autoinjector Market is estimated to be valued at US$ 2.50 Bn in 2024 and is expected to exhibit a CAGR of 8.9% over the forecast period 2024 To 2031.
Key Takeaways
Key players operating in the Global Epinephrine Autoinjector Market Trends are Mylan, Teva Pharmaceutical, Impax Laboratories, Adamis Pharmaceuticals Corporation, Pfizer, ALK Abello, Lincoln Medical, Hospira, Sanofi, Kaleo. Mylan dominates the market with their popular EpiPen brand. Teva Pharmaceutical's generic EpiPen launched in 2018 has increased competition in the market.
The surging number of food allergy cases, estimated to affect 10% children globally, has been a major demand driver for epinephrine auto-injectors. As per FAAN, food allergies affect 32 million Americans with prevalence rising each year. Launch of new therapeutics is expected to further boost auto-injector demand.
Technological advancements in auto-injector design for improved usability, increased shelf-life, alternate routes of administration and sensor-based connectivity are expected to support market growth. Smart connected auto-injectors with audio instructions and sensors to detect injection have entered the market.
Market Trends
Alternative epinephrine delivery routes like epinephrine inhalers and wearable devices are emerging.
Sensors and connectivity being incorporated in auto-injectors for real-time anaphylaxis management.
Market Opportunities
Pediatric epinephrine auto-injector market presents major growth opportunity with rising childhood food allergies.
Emerging markets of Asia Pacific and Latin America with growing allergy prevalence offer high growth potential.
Dual/multi-dose epinephrine auto-injectors and large volume options for adolescent/adult segment demand.
Impact of COVID-19 on Global Epinephrine Autoinjector Market:
The COVID-19 pandemic has significantly impacted the global epinephrine autoinjector market in both positive and negative ways. On the positive side, sales of epinephrine autoinjectors saw an increase in the initial months of the pandemic due to greater demand for emergency allergy treatment and preparedness. However, with lockdowns imposed worldwide, supply chain disruptions took place which impacted the regular manufacturing and distribution of autoinjectors.
Travel restrictions and social distancing norms reduced the chances of anaphylactic reactions initially. But as economies reopen and activities resume, the risks have increased. To combat this, pharmaceutical companies are ramping up production capacity while ensuring necessary safety protocols are followed. Telehealth and online channels have seen higher adoption to ensure patients faced with allergies can access medical advice and refill prescriptions remotely. National and international regulatory bodies have also streamlined approval processes to avoid shortages.
While the full impact of COVID-19 is yet to materialize, the market is expected to bounce back in the long run given the non-discretionary nature of epinephrine treatment. However, economic uncertainties caused by the pandemic may impact spending power in the short to medium term. Overall strategies by all stakeholders will play a key role in maintaining regular supply and supporting patients who require these lifesaving devices.
Geographical Regions with Highest Value Concentration in Global Epinephrine Autoinjector Market
In terms of value, North America accounts for the largest share in the global epinephrine autoinjector market. The region has prevalence of severe allergies along with established healthcare infrastructure and favorable reimbursement policies that boost adoption of autoinjectors. Within North America, the United States holds majority of the market owing to presence of major players and higher per capita income enabling device affordability.
Western Europe is another major regional market driven by growing cases of food allergies, increasing awareness about treatment and presence of key autoinjector brands. Countries like Germany, United Kingdom and France contribute significantly to the European market value. The Asia Pacific region is witnessing fastest growth and emerging as an important geographical area for epinephrine autoinjectors due to large patient pool and rising household incomes. China and India stand out as high potential developing markets.
Fastest Growing Region in Global Epinephrine Autoinjector Market:
The Asia Pacific region holds potential to be the fastest growing market for epinephrine autoinjectors globally over the forecast period from 2024 to 2031. This is attributed to rising incidences of anaphylaxis and growing diagnosis of conditions like food allergies among the large population in Asia Pacific countries. Increasing healthcare spending by governments and expansion of private insurance coverage is also propelling the demand.
Major factors fueling the Asia Pacific epinephrine autoinjector market growth include growing economies, large patient pools, rising living standards, increasing awareness about treatment of allergies and spread of modern lifestyles. Furthermore, entry and focus of leading global autoinjector manufacturers on the Asia Pacific region through partnerships will aid market penetration. China and India stand out as high potential markets within the region that are expected to drive the fastest growth.
Gets More Insights on: Global Epinephrine Autoinjector Market
Comments
0 comment